Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil
- 33 Downloads
In Brazil, patients with gastric cancer have not been systematically followed-up and evaluated, thus data regarding patterns of care and outcomes are scarce or missing. The objective of this study was to evaluate patterns of care of advanced gastric cancer in standard practice in Brazil.
This was an observational, multicenter, retrospective study, which included patients with metastatic and/or unresectable gastric cancer (MGC) who underwent at least one line of treatment.
We analyzed data on 155 patients diagnosed with MGC, most are men (57.4%), with mean age of 61.9 years at diagnosis, with 99 (63.9%) from the public healthcare system and 56 (36.1%) from the private setting. Platinum- and/or fluoropyrimidine-containing regimens prevailed as first-line therapy, while irinotecan was the most used regimen in the second and in the third lines. More than 40% of patients underwent only one line of systemic therapy, of which around 40% either died during the treatment or went on to best supportive care (BSC) only. The remaining patients received further treatment lines. A fifth of the patients in the study died within two months after discontinuation of the first-line treatment. Adverse events, use of concomitant medications, support procedures, outpatient visits, and hospitalizations were reported for most patients, especially in the first and second lines of treatment and during exclusive BSC.
Survival during or after the first-line chemotherapy remains poor among patients with MGC. Adverse events and health resource use were common in the first and second lines of treatment and in exclusive BSC. These results suggest that there is space for improvement in the treatment of MGC in Brazil.
KeywordsGastric cancer Metastatic/unresectable Treatment patterns Stomach neoplasm
Some findings of this paper were presented at the 19th European ISPOR Congress 2016 as a poster presentation with partial results. This study was funded by the Eli Lilly and Company. The authors are grateful for the support of Carolina Santinho, Christiane Bueno, Eloisa de Sá Moreira, Gabriel Prolla, Luiz Fernando Andrade Feijó, Renata Eiras Martins, Estela Federal, and Mayara Piani and all site staff involved in the study.
Compliance with Ethical Standards
Conflict of Interest
Diego Novick is an employee of Eli Lilly and Company Inc.; Eimy Minowa and Guilherme Silva Julian are employees of Kantar Health. The remaining authors declare that they have no conflicts of interest relevant to the manuscript submission.
This study was sponsored by Eli Lilly and Company.
- 1.International Agency for Research on Cancer (IARC). Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Lyon: GLOBOCAN; 2012. [Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx Google Scholar
- 2.Instituto Nacional do Câncer (INCA). Estimativas 2014: INCA; 2014 [Available from: http://www.inca.gov.br/estimativa/2014/tabelaestados.asp?UF=BR.
- 4.Coordenação INdCJAGdS, Vigilância. dPe. Estimativa 2016: incidência de câncer no Brasil Rio de Janeiro. 2015 [Available from: http://www.inca.gov.br/bvscontrolecancer/publicacoes/edicao/Estimativa_2016.pdf.
- 5.Arregi MMU, Férrer DPC, de Assis ECV, de Paiva FDS, Sobral LBG, André NF, et al. Perfil clínico-epidemiológico das neoplasias de estômago atendidas no Hospital do Câncer do Instituto do Câncer do Ceará, no período 2000-2004. Rev Bras Cancerol. 2009;55(2):121–8.Google Scholar
- 10.Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B. Treatment patterns, costs, and survival among Medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15(2):87–104.CrossRefGoogle Scholar
- 16.Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study—FFCD 9803. J Clin Oncol. 2004;22(21):4319–28.CrossRefGoogle Scholar
- 17.Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010(3):CD004064.Google Scholar
- 18.Hess LM, Michael D, Mytelka DS, Beyrer J, Liepa AM, Nicol S. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 2016;19(2):607–15.CrossRefGoogle Scholar
- 19.Brown J, Liepa A, Bapat B, Sleilaty G, Kaye J. Real-world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in France. Ann Oncol. 2015;26(Suppl 4):iv25.Google Scholar
- 20.National Comprehensive Cancer Network (NCCN). Gastric cancer [Available from: National Comprehensive Cancer Network].Google Scholar
- 22.Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306–14.CrossRefGoogle Scholar
- 24.Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44.CrossRefGoogle Scholar